Cargando…
Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study
Alveolar soft part sarcoma (ASPS), epithelioid sarcoma (ES), and clear cell sarcoma (CCS) are known to be chemoresistant tumors. The aim of this study was to investigate the effect of pazopanib on these chemoresistant tumors. This study is designed as a single‐arm, multicenter, investigator‐initiate...
Autores principales: | Urakawa, Hiroshi, Kawai, Akira, Goto, Takahiro, Hiraga, Hiroaki, Ozaki, Toshifumi, Tsuchiya, Hiroyuki, Nakayama, Robert, Naka, Norifumi, Matsumoto, Yoshihiro, Kobayashi, Eisuke, Okuma, Tomotake, Kunisada, Toshiyuki, Ando, Masahiko, Ueda, Takafumi, Nishida, Yoshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469808/ https://www.ncbi.nlm.nih.gov/pubmed/32579783 http://dx.doi.org/10.1111/cas.14542 |
Ejemplares similares
-
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study
por: Nakamura, Tomoki, et al.
Publicado: (2016) -
Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group
por: Nakamura, Tomoki, et al.
Publicado: (2020) -
A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup
por: Kawai, Akira, et al.
Publicado: (2016) -
Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study
por: Urakawa, Hiroshi, et al.
Publicado: (2018) -
Risk factors of local recurrence after surgery in extraabdominal desmoid‐type fibromatosis: A multicenter study in Japan
por: Nishida, Yoshihiro, et al.
Publicado: (2020)